Skip to main content

Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About
Trending Topics
    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Entertainment & Media
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor, Employment, and Benefits
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations
    Industries

    View All

    • Aviation
    • Cannabis
    • Consumer
    • Energy
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Nonprofit Organizations
    • Real Estate
    • Sports & Stadiums
    • Technology
    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Environmental, Social, and Governance (ESG)

      We help clients create positive return on investments in people, products, and the planet.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    • Women in Dealmaking

      We provide strategic counsel on complex corporate transactions and unite dynamic women in the dealmaking arena.

    1. Home
    2. Insights
    3. Alerts
    4. Oregon SB 951: Corporate practice of medicine law explained

      Alerts

    Alert / Healthcare

    Oregon SB 951: Corporate practice of medicine law explained

    July 11, 2025

    LinkedInX (Twitter)EmailCopy URL

    By Michele Masucci, Rebecca Simone, Jéna Grady, Jennifer Greco and Marissa Espinoza IcocheaLindsay Vaughn (Legal Intern—Healthcare practice) assisted with the preparation of this alert

    Oregon’s revised corporate practice of medicine law introduces sweeping restrictions on private equity, enacting the strictest limits in the nation.

    What’s the impact?

    • SB 951 bans dual ownership and restricts medical services organization (MSO) influence over clinical and business decisions, with phased compliance deadlines for existing and new MSOs.
    • The law limits restrictive covenants and compensation models that could affect clinical independence, requiring careful review of contracts and governance structures.

    DOWNLOAD

    Oregon SB 951: Corporate practice of medicine law explained (PDF)

    On June 9, 2025, Oregon Governor Tina Kotek signed Senate Bill 951 into law, marking a novel change in how states approach the regulation of ownership and control of certain professional medical entities by codifying and strengthening the corporate practice of medicine (“CPOM”) doctrine in Oregon. The effective date differs for regulating existing management services organizations (“MSOs”) versus new MSOs. Existing MSOs (those formed before enactment of the law on June 9, 2025) must come into compliance with the new law by January 1, 2029. For MSOs formed in Oregon on or after June 9, 2025, the law becomes effective on January 1, 2026.

    Key provisions of SB 951

    SB 951 expands Oregon’s longstanding CPOM prohibition by enacting new restrictions on the relationship between a MSO and a friendly professional medical entity[1] (“PME”) physician owners and licensed professionals who own or provide services through them. For purposes of this alert, “medical licensees” refers to physicians and other health professionals licensed to practice medicine in Oregon who are subject to the law’s restrictions. Notable provisions include the following:

    RESTRICTIONS ON OWNERSHIP AND CONTROL

    The law prohibits dual ownership by the licensed shareholders of the MSO and PMEs managed by the MSO. SB 951 prohibits shareholders, directors, members, managers, officers, and employees of an MSO from owning or controlling, collectively or individually, a majority of ownership interest in a PME that contracts with the MSO. SB 951 limits the use of stock transfer restriction agreements, with limited exceptions. The new law explicitly prohibits MSOs from making clinical decisions, which is not a meaningful shift from Oregon’s existing CPOM prohibition.

    GOVERNANCE RESTRICTIONS

    SB 951 imposes restrictions regarding director eligibility and governance rights. For example, it limits the ability of an MSO-affiliated individual to serve on the board of a PC and may prohibit governance provisions that confer de facto control. These provisions are aimed at preserving clinical independence by limiting MSO influence over entity governance.

    RESTRICTIVE COVENANTS

    The law limits noncompete, nondisclosure, and nondisparagement agreements. These limitations apply to agreements between MSOs and medical licensees, and are intended to ensure that such covenants do not interfere with reporting and accountability on PME operations. The exact scope of permissible restrictions may be further clarified through future rulemaking or enforcement actions.

    LIMITS ON EMPLOYMENT AND COMPENSATION MODELS

    SB 951 restricts employment and compensation structures that could unduly influence medical judgment. This includes arrangements where a medical licensee’s compensation is directly tied to MSO performance or investor profits.

    EXEMPTIONS

    The law contains exemptions, including hospitals, out-of-state telemedicine companies, and certain behavioral health entities. The law’s applicability is limited to “medical entities” and based on such definition, does not apply to practices owned by nonmedical providers, such as dentists or veterinarians.

    CONTRACTUAL CONTROL PROVISIONS

    SB 951 restricts the use of contractual provisions that confer certain financial or operational controls over a PME. Agreements that give an MSO — or an owner, employee, officer or the like of an MSO — decision-making authority may be deemed impermissible if they amount to de facto control over clinical or business operations. Agreements, such as stock transfer restriction agreements that allow the MSO to restrict the transfer of equity, are similarly prohibited.

    Implications for healthcare stakeholders

    The new law calls into question use of the MSO-friendly PME model. Even where MSOs do not hold equity stakes, contractual provisions granting financial or decision-making authority may be deemed unlawful under SB 951.

    As SB 951 is implemented, one issue to monitor is how the term “incidental,” as used in SB 951, is interpreted by Oregon regulators. The law provides an exception to the prohibition on dual MSO and PME ownership where individuals can own shares or an interest in an MSO that contracts with said PME if the individual’s ownership in the MSO is “incidental and without relation to the individual’s compensation as a shareholder, director, member, manager, officer[,] or employee of, or contractor” with the MSO. The potential flexibility embedded in this exception under SB 951 may present a valuable opportunity for stakeholders to preserve investments in MSOs under carefully structured arrangements.

    SB 951 may require a shift away from ownership-driven strategies and toward arm’s-length service models that preserve medical licensees’ autonomy. An MSO must also ensure that their scope of services do not violate the law’s prohibition on the MSO exerting “de facto control” over the administrative, business, or clinical operations of the entity.

    Next steps

    SB 951 will require providers, practices, MSOs, and investors to assess the structures of their PMEs and MSOs, the relationship between the parties, and contractual arrangements between the MSO and PME. Providers that rely on MSO partnerships for administrative and business support — and investors that use governance rights or profit-sharing arrangements to capture value — must take care to ensure they do not exert impermissible control over clinical operations.

    Organizations should begin reviewing administrative/management service agreements, governance documents, and compensation arrangements now to identify compliance with the new law.

    The phased compliance deadline offers an important opportunity for transition planning. At the same time, stakeholders should remain attentive to potential legislative amendments. House Bill 3410 — recently passed by both chambers of the Oregon legislature and awaiting the governor’s signature — is expected to modify or clarify aspects of SB 951, including definitions of “control” or permitted MSO activities. Additional rulemaking or interpretive guidance from state agencies may further shape how the law is applied in practice.

    Navigating new CPOM regulations

    The law sets a new benchmark for how far states may go in targeting, defining, and enforcing prohibitions regarding CPOM. Oregon’s actions reflect a larger nationwide effort by state legislators to increase regulatory oversight of healthcare ownership models. In California, for example, SB 351 proposes similar restrictions on private equity and MSO influence in medical practice.

    As SB 951 phases in over the coming years, healthcare providers, entities, MSOs, and investors should begin evaluating their current structures and arrangements for compliance. Organizations operating in Oregon, and those monitoring trends in other jurisdictions, should consult with legal counsel to assess their risk exposure and develop a compliance strategy that supports long-term growth.

    Nixon Peabody will continue to monitor state-by-state changes and Oregon’s implementation of SB 951 and developments related to HB 3410. For more information on this content, please contact your Nixon Peabody attorney or the authors of this alert.


    1. For purposes of SB 951 and this alert, “professional medical entity” includes professional corporations (PCs), professional limited liability companies (PLLCs), and other business organizations authorized to provide medical services in Oregon. The law applies to relationships involving a range of licensed medical professionals, including physicians, nurse practitioners (NPs), and physician assistants (PAs), among others.
      [back to reference ]

    Practices

    HealthcareHealthcare RestructuringHealthcare TransactionsHealthcare FinanceHealthcare Regulatory & CompliancePrivate Equity & Investment FundsCorporate & Finance

    Industries

    Healthcare

    Insights And Happenings

    • Alert

      CMS proposes updates to the Transforming Episode Accountability Model

      May 2, 2025
    • Article

      NYSDOH guidance on material transaction law

      March 26, 2025
    • Alert

      Proposed California legislation expands scrutiny of health care transactions

      March 25, 2025
    The foregoing has been prepared for the general information of clients and friends of the firm. It is not meant to provide legal advice with respect to any specific matter and should not be acted upon without professional counsel. If you have any questions or require any further information regarding these or other related matters, please contact your regular Nixon Peabody LLP representative. This material may be considered advertising under certain rules of professional conduct.

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • Cookie Preferences
    • Privacy Policy
    • Terms of Use
    • Accessibility Statement
    • Statement of Client Rights
    • Purchase Order Terms & Conditions
    • Nixon Peabody International LLC
    • PAL
    © 2025 Nixon Peabody. All rights reserved